<DOC>
	<DOCNO>NCT00351715</DOCNO>
	<brief_summary>The purpose Phase II study determine feasibility dose titration assessment protocol outpatient population conduct appropriately power phase III study . Thus primary purpose study determine proportion patient successfully titrate optimal dose sublingual ( Under tongue ) methadone study optimal dose successive episode breakthrough pain .</brief_summary>
	<brief_title>Sublingual Methadone Management Cancer-related Breakthrough Pain Outpatients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Pain due cancer treatment ; control baseline pain ; episode breakthrough pain every day `` 4/10 '' severity great , ; ast 10 minute longer , responsive short act oral opioids morphine hydromorphone ; able hole volume 1.0cc water tongue 5minute period ; able provide write informed consent ; able fill study form Severe underlie respiratory disease investigator wary risk respiratory failure modest dose opioid ; prior sensitivity methadone ; currently administered methadone ; breakthrough pain opinion investigator likely change within next seven day ( recent imminent radiation therapy main site pain , new chemotherapy use injectable bisphosphonate likely alter pain , new use corticosteroid within past week correspond change pain , intervention judge likely alter pain ) ; clinically unstable life expectancy le one month make completion trial unlikely</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Sublingual Methadone</keyword>
	<keyword>Cancer relate breakthrough pain</keyword>
	<keyword>feasibility study</keyword>
	<keyword>Phase II/open label</keyword>
	<keyword>Outpatients</keyword>
	<keyword>Safety/ efficacy</keyword>
	<keyword>previously receive opioids</keyword>
	<keyword>speak English</keyword>
</DOC>